S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

Podobne zapisy

• Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
  od: Dayu Wu, i wsp.
  Wydane: (2022-08-01)
• Bromodomain and extra-terminal proteins in solid tumors: regulators of immune microenvironment and emerging therapeutic targets
  od: Deeksha Sharma, i wsp.
  Wydane: (2026-01-01)
• EV BMS With Charge Monitor and Fire Detection
  od: Mastanamma Y., i wsp.
  Wydane: (2024-01-01)
• Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
  od: Andrew Groves, i wsp.
  Wydane: (2022-05-01)
• A Minireview on BET Inhibitors: Beyond Bromodomain Targeting
  od: Mikhail S. Iudin, i wsp.
  Wydane: (2025-03-01)